{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T16:16:22Z","timestamp":1788365782168,"version":"build-2803163510"},"reference-count":115,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001721","name":"Rijksuniversiteit Groningen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001721","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ymthe.2026.06.043","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T12:53:05Z","timestamp":1783601585000},"page":"5055-5069","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Are the current preclinical models adequate to evaluate CAR-T cell therapy in pediatric high-grade gliomas?"],"prefix":"10.1016","volume":"34","author":[{"given":"Ana Mu\u00f1oz","family":"Grau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Hameedat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bibi Sumayyah","family":"Hussein Sokeechand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitra","family":"Venugopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6587-6175","authenticated-orcid":false,"given":"Fl\u00e1via","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.06.043_bib1","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S1470-2045(25)00297-9","article-title":"Long-term survival and cure fraction estimates for paediatric central nervous system tumours in 31 European countries (EUROCARE-6): a population-based study","volume":"26","author":"Hoogendijk","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ymthe.2026.06.043_bib2","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ymthe.2026.06.043_bib3","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s10555-024-10208-4","article-title":"CAR T cell therapy for pediatric central nervous system tumors: a review of the literature and current North American trials","volume":"43","author":"Ronsley","year":"2024","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ymthe.2026.06.043_bib4","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.3390\/cells10112940","article-title":"Facing CAR T Cell Challenges on the Deadliest Paediatric Brain Tumours","volume":"10","author":"Ferreras","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.ymthe.2026.06.043_bib5","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.3390\/cells13171492","article-title":"Emerging and Biological Concepts in Pediatric High-Grade Gliomas","volume":"13","author":"Yoel","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.ymthe.2026.06.043_bib6","article-title":"European standard clinical practice recommendations for paediatric high-grade gliomas","volume":"5","author":"Szychot","year":"2025","journal-title":"EJC Paediatr. Oncol."},{"key":"10.1016\/j.ymthe.2026.06.043_bib7","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.ymthe.2026.06.043_bib8","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3390\/biology13060424","article-title":"The Landscape of Pediatric High-Grade Gliomas: The Virtues and Pitfalls of Pre-Clinical Models","volume":"13","author":"Furst","year":"2024","journal-title":"Biology"},{"key":"10.1016\/j.ymthe.2026.06.043_bib9","doi-asserted-by":"crossref","DOI":"10.4028\/b-dOXV17","article-title":"Epigenomic landscape and 3D genome structure in pediatric high-grade glioma","volume":"7","author":"Wang","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2026.06.043_bib10","article-title":"Dissecting the immune landscape in pediatric high-grade glioma reveals cell state changes under therapeutic pressure","volume":"6","author":"LaBelle","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ymthe.2026.06.043_bib11","article-title":"The road to CAR-T-cell therapy for lethal childhood brain tumours","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.06.043_bib12","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The Basic Principles of Chimeric Antigen Receptor Design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ymthe.2026.06.043_bib13","doi-asserted-by":"crossref","first-page":"105266","DOI":"10.1016\/j.ebiom.2024.105266","article-title":"Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment","volume":"106","author":"Bui","year":"2024","journal-title":"eBioMedicine"},{"key":"10.1016\/j.ymthe.2026.06.043_bib14","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.3390\/cancers14112814","article-title":"Novel Pharmacological Treatment Options in Pediatric Glioblastoma-A Systematic Review","volume":"14","author":"Wyss","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ymthe.2026.06.043_bib15","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1182\/blood-2018-99-112572","article-title":"Checkpoint Inhibitors Augment CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Relapsed B-Cell Acute Lymphoblastic Leukemia","volume":"132","author":"Li","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.06.043_bib16","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.06.043_bib17","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.06.043_bib18","first-page":"360","article-title":"Glioblastoma microenvironment-from biology to therapy","volume":"38","author":"Read","year":"2024","journal-title":"Genes Dev."},{"key":"10.1016\/j.ymthe.2026.06.043_bib19","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s11060-024-04909-7","article-title":"Clinical progress in the development of CAR T cells to treat malignant glioma","volume":"171","author":"Grewal","year":"2025","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.ymthe.2026.06.043_bib20","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/j.ymthe.2025.03.005","article-title":"From concept to cure: The evolution of CAR-T cell therapy","volume":"33","author":"Patel","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.06.043_bib21","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41586-024-08171-9","article-title":"Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas","volume":"637","author":"Monje","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.06.043_bib22","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/s41591-024-03451-3","article-title":"Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial","volume":"31","author":"Vitanza","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.06.043_bib23","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1038\/s41467-019-11869-4","article-title":"CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors","volume":"10","author":"Jin","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.06.043_bib24","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","article-title":"CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors","volume":"25","author":"Majzner","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.06.043_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011698","article-title":"Predictive value of preclinical models for CAR-T cell therapy clinical trials: a systematic review and meta-analysis","volume":"13","author":"Andreu-Sanz","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2026.06.043_bib27","doi-asserted-by":"crossref","first-page":"5972","DOI":"10.3390\/cancers14235972","article-title":"Three-Dimensional Cell Culture Systems in Pediatric and Adult Brain Tumor Precision Medicine","volume":"14","author":"Riedel","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ymthe.2026.06.043_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2025.189455","article-title":"Animal models in preclinical evaluation of CAR-T cell therapy: Advantages and limitations","volume":"1880","author":"Fl\u00f8e","year":"2025","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.ymthe.2026.06.043_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.ads0449","article-title":"The immunology of brain tumors","volume":"10","author":"Bunse","year":"2025","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.ymthe.2026.06.043_bib30","doi-asserted-by":"crossref","first-page":"736","DOI":"10.3390\/biology12050736","article-title":"Tumor Microenvironment and Glioblastoma Cell Interplay as Promoters of Therapeutic Resistance","volume":"12","author":"Agosti","year":"2023","journal-title":"Biology"},{"key":"10.1016\/j.ymthe.2026.06.043_bib31","doi-asserted-by":"crossref","first-page":"102353","DOI":"10.1016\/j.xcrm.2025.102353","article-title":"CAR-T cells in solid tumors: Challenges and breakthroughs","volume":"6","author":"Escobar","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ymthe.2026.06.043_bib32","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1093\/neuonc\/noaf007","article-title":"Establishing a living biobank of pediatric high-grade glioma and ependymoma suitable for cancer pharmacology","volume":"27","author":"Deligne","year":"2025","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.ymthe.2026.06.043_bib33","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/neuonc\/noad207","article-title":"Tumor and immune cell types interact to produce heterogeneous phenotypes of pediatric high-grade glioma","volume":"26","author":"DeSisto","year":"2024","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.ymthe.2026.06.043_bib34","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41556-024-01583-9","article-title":"Mapping the developmental trajectory of human astrocytes reveals divergence in glioblastoma","volume":"27","author":"Sojka","year":"2025","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ymthe.2026.06.043_bib35","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.trecan.2022.10.010","article-title":"Neuronal and tumourigenic boundaries of glioblastoma plasticity","volume":"9","author":"De Silva","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ymthe.2026.06.043_bib36","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s00401-020-02155-5","article-title":"Pediatric bithalamic gliomas have a distinct epigenetic signature and frequent EGFR exon 20 insertions resulting in potential sensitivity to targeted kinase inhibition","volume":"139","author":"Mondal","year":"2020","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ymthe.2026.06.043_bib37","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ccell.2021.01.005","article-title":"H3.3-K27M drives neural stem cell-specific gliomagenesis in a human iPSC-derived model","volume":"39","author":"Haag","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2026.06.043_bib38","doi-asserted-by":"crossref","first-page":"27354","DOI":"10.1073\/pnas.2006076117","article-title":"Histone H3.3 G34 mutations promote aberrant PRC2 activity and drive tumor progression","volume":"117","author":"Jain","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.06.043_bib39","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1158\/2159-8290.CD-12-0426","article-title":"Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN","volume":"3","author":"Bjerke","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ymthe.2026.06.043_bib40","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ccell.2017.08.017","article-title":"Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma","volume":"32","author":"Mackay","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2026.06.043_bib41","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s40478-025-01961-w","article-title":"Metabolic profiling of adult and pediatric gliomas reveals enriched glucose availability in pediatric gliomas and increased fatty acid oxidation in adult gliomas","volume":"13","author":"Sviderskiy","year":"2025","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.ymthe.2026.06.043_bib42","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41698-025-00830-y","article-title":"An integrated perspective on single-cell and spatial transcriptomic signatures in high-grade gliomas","volume":"9","author":"Lemoine","year":"2025","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.ymthe.2026.06.043_bib43","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.cell.2023.02.002","article-title":"Cancer neuroscience: state of the field, emerging directions","volume":"186","author":"Winkler","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2026.06.043_bib44","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41586-019-1564-x","article-title":"Glutamatergic synaptic input to glioma cells drives brain tumour progression","volume":"573","author":"Venkataramani","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.06.043_bib45","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1016\/j.cell.2022.06.054","article-title":"Glioblastoma hijacks neuronal mechanisms for brain invasion","volume":"185","author":"Venkataramani","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2026.06.043_bib46","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41586-023-06678-1","article-title":"Glioma synapses recruit mechanisms of adaptive plasticity","volume":"623","author":"Taylor","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.06.043_bib47","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.cell.2015.04.012","article-title":"Neuronal Activity Promotes Glioma Growth through Neuroligin-3 Secretion","volume":"161","author":"Venkatesh","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2026.06.043_bib48","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/neuonc\/nox070","article-title":"Tumor microtubes convey resistance to surgical lesions and chemotherapy in gliomas","volume":"19","author":"Weil","year":"2017","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.ymthe.2026.06.043_bib49","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S1470-2045(17)30517-X","article-title":"Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ymthe.2026.06.043_bib50","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/s41577-025-01229-3","article-title":"Microenvironmental regulation of solid tumour resistance to CAR T cell therapy","volume":"26","author":"Lamplugh","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2026.06.043_bib51","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1016\/j.immuni.2024.09.007","article-title":"Microglia and monocyte-derived macrophages drive progression of pediatric high-grade gliomas and are transcriptionally shaped by histone mutations","volume":"57","author":"Ross","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2026.06.043_bib52","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1007\/s00262-021-03131-y","article-title":"Pediatric glioblastoma: mechanisms of immune evasion and potential therapeutic opportunities","volume":"71","author":"Njonkou","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ymthe.2026.06.043_bib53","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41698-024-00755-y","article-title":"Pediatric brain tumor patients display altered immune activation and reduced lymphopoiesis at the onset of disease","volume":"8","author":"Rosichini","year":"2024","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.ymthe.2026.06.043_bib54","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1016\/j.ymthe.2025.02.043","article-title":"Killing the killers: Natural killer cell therapy targeting glioma stem cells in high-grade glioma","volume":"33","author":"Poorva","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.06.043_bib55","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.3389\/fonc.2020.01582","article-title":"CAR T Cell Therapy for Pediatric Brain Tumors","volume":"10","author":"Patterson","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymthe.2026.06.043_bib56","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.trecan.2023.07.007","article-title":"CAR T cell therapies for diffuse midline glioma","volume":"9","author":"Thomas","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ymthe.2026.06.043_bib57","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.3390\/cancers14092296","article-title":"Glioma Stem Cells in Pediatric High-Grade Gliomas: From Current Knowledge to Future Perspectives","volume":"14","author":"Da-Veiga","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ymthe.2026.06.043_bib58","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/s41416-022-01864-w","article-title":"Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them","volume":"127","author":"Habashy","year":"2022","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ymthe.2026.06.043_bib59","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s10555-024-10183-w","article-title":"Glioblastoma stem cell metabolism and immunity","volume":"43","author":"Hawly","year":"2024","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ymthe.2026.06.043_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104648","article-title":"CAR T-cell therapy landscape in pediatric, adolescent and young adult oncology \u2013 A comprehensive analysis of clinical trials","volume":"209","author":"Mart\u00ednez-Gamboa","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ymthe.2026.06.043_bib61","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2217\/cns-2016-0016","article-title":"Clinical trials in pediatric neuro-oncology: what is missing and how we can improve","volume":"5","author":"Byer","year":"2016","journal-title":"CNS Oncol."},{"key":"10.1016\/j.ymthe.2026.06.043_bib62","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ymthe.2026.06.043_bib63","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adp2660","article-title":"Next-generation CAR T cell therapies for glioblastoma","volume":"16","author":"Bernstock","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.06.043_bib64","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","article-title":"GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma","volume":"388","author":"Del Bufalo","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.06.043_bib65","doi-asserted-by":"crossref","DOI":"10.1097\/BS9.0000000000000247","article-title":"CD7 CAR-T therapy: current developments, improvements, and dilemmas","volume":"7","author":"Wang","year":"2025","journal-title":"Blood Sci."},{"key":"10.1016\/j.ymthe.2026.06.043_bib66","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.3390\/ijms25137174","article-title":"CAR-T Cells Therapy in Glioblastoma: A Systematic Review on Molecular Targets and Treatment Strategies","volume":"25","author":"Agosti","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2026.06.043_bib67","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1158\/1078-0432.CCR-15-0428","article-title":"Bioactivity and Safety of IL13R\u03b12-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma","volume":"21","author":"Brown","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.06.043_bib68","article-title":"Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13R\u03b12 are effective against heterogeneous glioblastoma","volume":"5","author":"Schmidts","year":"2023","journal-title":"Neurooncol. Adv."},{"key":"10.1016\/j.ymthe.2026.06.043_bib69","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3390\/cancers16030623","article-title":"Chimeric Antigen Receptor T Cell and Chimeric Antigen Receptor NK Cell Therapy in Pediatric and Adult High-Grade Glioma\u2014Recent Advances","volume":"16","author":"Kowalczyk","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.ymthe.2026.06.043_bib70","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/2326-6066.CIR-13-0027","article-title":"Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity","volume":"2","author":"Wang","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2026.06.043_bib71","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41698-025-01079-1","article-title":"GD2: hopes and challenges for the treatment of pediatric patients with tumors of the central nervous system","volume":"9","author":"Fern\u00e1ndez-Rilo","year":"2025","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.ymthe.2026.06.043_bib72","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/PPO.0000000000000609","article-title":"Preclinical In Vitro and In Vivo Models for Adoptive Cell Therapy of Cancer","volume":"28","author":"Kaushik","year":"2022","journal-title":"Cancer J."},{"key":"10.1016\/j.ymthe.2026.06.043_bib73","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s11912-025-01672-4","article-title":"Evolution of Preclinical Models for Glioblastoma Modelling and Drug Screening","volume":"27","author":"Thomas","year":"2025","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.ymthe.2026.06.043_bib74","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.3390\/cells13171480","article-title":"Pre-Clinical Models for CAR T-Cell Therapy for Glioma","volume":"13","author":"Vandecandelaere","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.ymthe.2026.06.043_bib75","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.3390\/ijms22062962","article-title":"Advanced Spheroid, Tumouroid and 3D Bioprinted In-Vitro Models of Adult and Paediatric Glioblastoma","volume":"22","author":"Orcheston-Findlay","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2026.06.043_bib76","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.3390\/ijms23063154","article-title":"Preclinical Evaluation of CAR T Cell Function: In Vitro and In Vivo Models","volume":"23","author":"Si","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2026.06.043_bib77","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.3390\/cancers15194846","article-title":"Three-Dimensional In Vitro Tumor Spheroid Models for Evaluation of Anticancer Therapy: Recent Updates","volume":"15","author":"Nayak","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ymthe.2026.06.043_bib78","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.cels.2024.11.011","article-title":"Microengineered in vitro CAR T cell screens and assays","volume":"15","author":"Kim","year":"2024","journal-title":"Cell Syst."},{"key":"10.1016\/j.ymthe.2026.06.043_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.115449","article-title":"Tumor organoids targeted by receptor-engineered immune cells: A promising approach for advancing cancer immunotherapy","volume":"165","author":"Zhang","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ymthe.2026.06.043_bib80","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1038\/s41467-021-24168-8","article-title":"Patient-derived models recapitulate heterogeneity of molecular signatures and drug response in pediatric high-grade glioma","volume":"12","author":"He","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.06.043_bib81","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41592-018-0070-7","article-title":"Genetically engineered cerebral organoids model brain tumor formation","volume":"15","author":"Bian","year":"2018","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ymthe.2026.06.043_bib82","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41586-019-1563-y","article-title":"Electrical and synaptic integration of glioma into neural circuits","volume":"573","author":"Venkatesh","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.06.043_bib83","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/neuonc\/noae245","article-title":"Neuroimmune-competent human brain organoid model of diffuse midline glioma","volume":"27","author":"Sarnow","year":"2025","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.ymthe.2026.06.043_bib84","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12987-022-00342-y","article-title":"Application of blood brain barrier models in pre-clinical assessment of glioblastoma-targeting CAR-T based immunotherapies","volume":"19","author":"Huang","year":"2022","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.ymthe.2026.06.043_bib85","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.omtm.2022.08.008","article-title":"Applying a clinical lens to animal models of CAR-T cell therapies","volume":"27","author":"Duncan","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2026.06.043_bib86","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.3390\/cancers16183186","article-title":"Syngeneic Mouse Models for Pre-Clinical Evaluation of CAR T Cells","volume":"16","author":"Ahmed","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.ymthe.2026.06.043_bib87","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1158\/2159-8290.CD-23-0004","article-title":"A Compendium of Syngeneic, Transplantable Pediatric High-Grade Glioma Models Reveals Subtype-Specific Therapeutic Vulnerabilities","volume":"13","author":"McNicholas","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ymthe.2026.06.043_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2020.100165","article-title":"Genetically Engineered Mouse Model of Brainstem High-Grade Glioma","volume":"1","author":"Nunez","year":"2020","journal-title":"STAR Protoc."},{"key":"10.1016\/j.ymthe.2026.06.043_bib89","doi-asserted-by":"crossref","first-page":"7717","DOI":"10.1038\/s41467-023-43564-w","article-title":"Mouse models of pediatric high-grade gliomas with MYCN amplification reveal intratumoral heterogeneity and lineage signatures","volume":"14","author":"Schoof","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.06.043_bib90","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s40478-022-01428-2","article-title":"Human induced pluripotent stem cell engineering establishes a humanized mouse platform for pediatric low-grade glioma modeling","volume":"10","author":"Anastasaki","year":"2022","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.ymthe.2026.06.043_bib91","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00005-018-0506-x","article-title":"Humanized Mice as Unique Tools for Human-Specific Studies","volume":"66","author":"Yong","year":"2018","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"10.1016\/j.ymthe.2026.06.043_bib92","doi-asserted-by":"crossref","first-page":"6153","DOI":"10.1158\/0008-5472.CAN-16-1260","article-title":"Humanized mouse xenograft models: narrowing the tumor-microenvironment gap","volume":"76","author":"Morton","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2026.06.043_bib93","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/s41390-025-03847-y","article-title":"Opportunities in the translational pipeline for pediatric brain cancer therapies","volume":"98","author":"Rumberger Rivera","year":"2025","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ymthe.2026.06.043_bib94","doi-asserted-by":"crossref","first-page":"6127","DOI":"10.1111\/febs.15739","article-title":"Pediatric high-grade glioma: moving toward subtype-specific multimodal therapy","volume":"288","author":"Chatwin","year":"2021","journal-title":"FEBS J."},{"key":"10.1016\/j.ymthe.2026.06.043_bib95","article-title":"Programs, Origins, and Niches of Immunomodulatory Myeloid Cells in Gliomas","author":"Miller","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/j.ymthe.2026.06.043_bib96","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202503384","article-title":"Prediction of CAR-T Therapy In Vitro: Development of Biomimetic Models for CAR-T Killing Effect Assessment","volume":"21","author":"Sun","year":"2025","journal-title":"Small"},{"key":"10.1016\/j.ymthe.2026.06.043_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.crbiot.2024.100210","article-title":"In vitro and in vivo experimental models for cancer immunotherapy study","volume":"7","author":"Zhang","year":"2024","journal-title":"Curr. Res. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.06.043_bib98","first-page":"145","article-title":"Management of high-grade gliomas in the pediatric patient: Past, present, and future","volume":"1","author":"Vanan","year":"2014","journal-title":"Neurooncol. Pract."},{"key":"10.1016\/j.ymthe.2026.06.043_bib99","doi-asserted-by":"crossref","first-page":"64564","DOI":"10.18632\/oncotarget.18478","article-title":"High-grade glioma in very young children: a rare and particular patient population","volume":"8","author":"El-Ayadi","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2026.06.043_bib100","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/s12967-024-05063-4","article-title":"CAR T cells and T cells phenotype and function are impacted by glucocorticoid exposure with different magnitude","volume":"22","author":"Poiret","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.06.043_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116532","article-title":"Efficient combination of radiotherapy and CAR-T \u2013 A systematic review","volume":"174","author":"Szlasa","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ymthe.2026.06.043_bib102","article-title":"CAR-T Plus Radiotherapy: A Promising Combination for Immunosuppressive Tumors","volume":"12","author":"Qin","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.06.043_bib103","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1186\/s12935-022-02778-6","article-title":"CAR-T cell combination therapy: the next revolution in cancer treatment","volume":"22","author":"Al-Haideri","year":"2022","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ymthe.2026.06.043_bib104","doi-asserted-by":"crossref","first-page":"1140541","DOI":"10.3389\/fimmu.2023.1140541","article-title":"Combining chemotherapy with CAR-T cell therapy in treating solid tumors","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.06.043_bib105","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.4049\/jimmunol.1301119","article-title":"Synergistic Chemoimmunotherapy of Epithelial Ovarian Cancer Using ErbB-Retargeted T Cells Combined with Carboplatin","volume":"191","author":"Parente-Pereira","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2026.06.043_bib106","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1182\/blood.2019001641","article-title":"Toxicity and response after CD19-specific CAR T-cell therapy in pediatric\/young adult relapsed\/refractory B-ALL","volume":"134","author":"Curran","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.06.043_bib107","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ncponc0666","article-title":"Increased intensity lymphodepletion and adoptive immunotherapy\u2014how far can we go?","volume":"3","author":"Muranski","year":"2006","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"10.1016\/j.ymthe.2026.06.043_bib108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CJI.0b013e3181b88ffc","article-title":"Increased Intensity Lymphodepletion Enhances Tumor Treatment Efficacy of Adoptively Transferred Tumor-specific T Cells","volume":"33","author":"Wrzesinski","year":"2010","journal-title":"J. Immunother."},{"key":"10.1016\/j.ymthe.2026.06.043_bib109","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1084\/jem.20050732","article-title":"Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells","volume":"202","author":"Gattinoni","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymthe.2026.06.043_bib110","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.06.043_bib111","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1046\/j.1365-2567.2002.01400.x","article-title":"T-cell dynamics after high-dose chemotherapy in adults: elucidation of the elusive CD8+ subset reveals multiple homeostatic T-cell compartments with distinct implications for immune competence","volume":"106","author":"Fagnoni","year":"2002","journal-title":"Immunology"},{"key":"10.1016\/j.ymthe.2026.06.043_bib112","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13058-015-0669-x","article-title":"Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer","volume":"18","author":"Verma","year":"2016","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ymthe.2026.06.043_bib113","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4+ CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.06.043_bib114","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1182\/blood.2020008865","article-title":"Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma","volume":"137","author":"Strati","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.06.043_bib115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1009504","article-title":"Dose-dependent thresholds of dexamethasone destabilize CAR T-cell treatment efficacy","volume":"18","author":"Brummer","year":"2022","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.ymthe.2026.06.043_bib116","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1080\/10428194.2020.1786563","article-title":"Patient selection for chimeric antigen receptor (CAR) T-cell therapy for aggressive B-cell non-Hodgkin lymphomas","volume":"61","author":"Johnson","year":"2020","journal-title":"Leuk. Lymphoma"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626005733?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626005733?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:21:30Z","timestamp":1788362490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001626005733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":115,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1525001626005733"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.06.043","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Are the current preclinical models adequate to evaluate CAR-T cell therapy in pediatric high-grade gliomas?","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.06.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}